Tanshinone IIA protects against cardiac hypertrophy via inhibiting cal-cineurin/Nfatc3 pathway

International Journal of Biological Sciences

Volumn 7, Issue 3, 2011, Pages 383-389

  Tan, Xueying ^a   Li, Jianping ^a   Wang, Xinyue ^a   Chen, Nan ^a   Cai, Benzhi ^a   Wang, Gang ^a   Shan, Hongli ^a   Dong, Deli ^a   Liu, Yanju ^a   Li, Xingda ^a   Yang, Fan ^a   Li, Xin ^a   Zhang, Peng ^a   Li, Xueqi ^a   Yang, Baofeng ^a   Lu, Yanjie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin; Cardiac hypertrophy; Isoproterenol; NFATc3; Tanshinone IIA

Indexed keywords

SALVIA MILTIORRHIZA;

EID: 79955526513     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.383     Document Type: Article

References (28)

1. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent tran-scriptional pathway for cardiac hypertrophy. Cell. 1998; 93(2):215-228.
2. Hunter JJ, Chien KR. Signaling pathways for cardiac hyper-trophy and failure. N Engl J Med. 1999; 341(17):1276-1283.
3. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W, Yang BF. Reciprocal repression between mi-croRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hyper-tension. 2010; 55(4):946-952.
4. Osadchii OE. Cardiac hypertrophy induced by sustained be-ta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev. 2007;12(1):66-86
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322(22):1561-1566.
6. Wu B, Liu M, Zhang S. Dan Shen agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;18:CD004295.
7. Bi HC, Zuo Z, Chen X, Xu CS, Wen YY, Sun HY, Zhao LZ, Pan Y, Deng Y, Liu PQ, Gu LQ, Huang ZY, Zhou SF, Huang M. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Sal-via miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiotica. 2008; 38: 185-222.
8. Oh SH, Cho KH, Yang BS, Roh YK. Natural compounds from Danshen suppress the activity of hepatic stellate cells. Arch Pharm Res. 2006; 29:762-767.
9. Lee CY, Sher HF, Chen HW, Liu CC, Chen CH, Lin CS, Yang PC, Tsay HS, Chen JJ. Anticancer effects of tanshinone I in hu-man non-small cell lung cancer. Mol Cancer Ther. 2008; 7(11):3527-3538
10. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chem-istry, pharmacology, pharmacokinetics, and clinical use. J Cell Biochem. 2005;45:1345-1359.
11. Wu TW, Zeng LH, Fung KP, Wu J, Pang H, Grey AA, Weisel RD, Wang JY. Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascu-lar endothelial cells. Biochem Pharmacol. 1993;:2327-2332.
12. Lin R, Wang WR, Liu JT, Yang GD, Han CJ. Protective effect of tanshinone IIA on human umbilical vein endothelial cell in-jured by hydrogen peroxide and its mechanism. J Ethnophar-macol. 2006;:217-222.
13. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA pro-tects cardiac myocytes against oxidative stress-triggered dam-age and apoptosis. Eur J Pharmacol. 2007; 568(1-3):213-221
14. Yang L, Zou X, Liang Q, Chen H, Feng J, Yan L, Wang Z, Zhou D, Li S, Yao S, Zheng Z. Sodium tanshinone IIA sulfonate de-presses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp Mol Med. 2007;39(1):65-73.
15. Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang Y, Xu C, Chu W, Qiao G, Li B, Lu Y, Yang B. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via re-pression of microRNA-1. Br J Pharmacol. 2009; 158(5):1227-1235.
16. Cai BZ, Zhao LM, Wang N, Liu JQ, Zhu SL, Meng FY, Zhou HY, Lu YJ, Ai J, Yang BF. Bone marrow mesenchymal stem cells upregulate transient outward potassium currents in postnatal rat ventricular myocytes. J Mol Cell Cardiol. 2009;47(1):41-48.
17. Hong HM, Song EJ, Oh E, Kabir MH, Lee C, Yoo YS. Endo-thelin-1- and isoproterenol-induced differential protein expres-sion and signaling pathway in HL-1 cardiomyocytes. Prote-omics. 2011;11(2):283-297.
18. Liggett SB. Pharmacogenetics of beta-1 and beta-2-adrenergic receptors. Pharmacology. 2000; 61(3):167-173.
19. Morisco C, Marrone C, Galeotti J, Shao D, Vatner DE, Vatner SF, Sadoshima J. Endocytosis machinery is required for be-ta1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes. Cardiovasc Res. 2008;78(1):36-44.
20. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT cou-pling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94(1):110-118.
21. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002; 22(21):7603-7613.
22. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009;106(29):12103-12108.
23. Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem. 2010;285(16):11903-11912.
24. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol.2007;121: 9-22.
25. Leenen FH, White R, Yuan B. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac ren-in-angiotensin system. Am J Physiol Heart Circ Physiol. 2001; 281(6):H2410-H2416.
26. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, Xu H, Florio V, Rybalkin SD, Beavo JA, Chen YF, Li JD, Blaxall BC, Abe J, Yan C. Role of Ca2+/calmodulin-stimulated cyclic nu-cleotide phosphodiesterase 1 in mediating cardiomyocyte hy-pertrophy. Circ Res. 2009;105(10):956-964.
27. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
28. Yeh JL, Hsu JH, Wu PJ, Liou SF, Liu CP, Chen IJ, Wu BN, Dai ZK, Wu JR. KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathway. Br J Pharmacol. 2010; 159: 1151-1160